| Prev Close | 4.62 |
| Day Low/High | 4.57 / 4.95 |
| 52 Wk Low/High | 2.85 / 7.21 |
| Avg Volume | 1.12M |
BioDelivery Sciences International Inc. (BDSI)
4.93
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 99.89M |
| Market Cap | 461.49M |
| EPS | -0.20 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
2 Small Biopharma Stocks That Should Perk Up as Nation Returns to Work
Flexion Therapeutics and BioDelivery Sciences International have promising products that should do well once the fixation on Covid-19 treatments wanes.
These 2 Stocks Should Easily Withstand the Economic Impacts of Covid-19
DropBox and BioDelivery Sciences are names to consider during the market choppiness of the coming weeks.
Adding to My Biotech Positions When Profit-Taking Hits
Here's my strategy which has worked particularly well.
3 Small-Cap Biotech Stocks That Could Thrive in 2020
The trio of BioDelivery Sciences, Omeros and TG Therapeutics looks well-positioned to capitalize on their potential in the New Year.
3 Small Biotechs With Favorable Risk Vs. Reward Profiles
BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.
3 Small-Caps That Look Like Bargains at Current Trading Levels
The trio consists of BioDelivery Sciences International, Beazer Homes USA and Redhill Biopharma.
These Two Small-Cap Stocks Are Executing Well
Both Digital Turbine and BioDelivery Sciences have done well in 2019.
Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs
I am incrementally using buy-write option orders to add some shares to core holdings.
These 3 Biotech Stocks Are Moving Closer to Profitability
Here are updates on small biotech/biopharma names I have profiled before.
My Post-Earnings Assessment of 2 Biotech Stocks
Let's look at a couple of companies we have covered on these pages before.
3 Small Biotechs to Watch as Earnings Season Winds Down
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
Here Are 3 Small-Cap Names for Biotech Investors to Consider
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
3 Small Biotechs That Came Up Big on Thursday
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
3 Small Biotechs Turn on the Revenue Jets
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
4 Small-Caps on My Earnings Watch List
We are coming my favorite part of earnings season -- when these small-caps report.
3 Biotech Stocks on Readers' Minds
We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.
Trump's FDA: A Friendlier Biotech Sheriff
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
2 Recovering Biotech Names With Room to Run
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
4 Undervalued Biotech Stocks
Two are turnaround stories, and two are oversold.
2 Oversold Biopharmas With Big 2017 Upsides
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
3 Small Biotech Value Plays
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
Welcome to the Small-Cap Biotech Mailbag!
We answer recent reader questions about three of the biotech stocks we regularly cover.
BioDelivery Sciences Showing Strength
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid first trading week of 2017 on a high note. Think Teva Pharmaceuticals getting oversold today on slightly r...
My Top 2017 Pick: Progenics Pharmaceuticals
This biopharma company's Relistor drug should send revenues sharply higher this year.
Top 2017 Pick: Progenics Pharmaceuticals
This biopharma company's Relistor drug should send revenues sharply higher next year.
